MASHTrialPulse 2026-04-26

Disclaimer: 본 도구는 연구·교육 목적의 참고용이며, 임상시험 등록·MASH 처방·임상 의사결정 근거로 사용할 수 없습니다. 모든 데이터는 합성(synthetic)입니다.

ClinicalTrials.gov diff (synthetic)

pipeline retatrutide의 Eli Lilly이 2026-04-26에 Phase 2 신규 trial 등록을 보고함.

영향 약물: retatrutide · id: NCT09000113 · detail: 신규 trial 등록: Retatrutide TRIUMPH-MASH-Synth Phase 2 (synthetic) (Phase 2)

pipeline VK2809의 Viking이 2026-04-26에 Phase 2b 신규 trial 등록을 보고함.

영향 약물: VK2809 · id: NCT09000114 · detail: 신규 trial 등록: VK2809 VOYAGE-Synth MASH F2-F3 (synthetic) (Phase 2b)

pipeline survodutide의 Boehringer이 2026-04-26에 phase Phase 2 -> Phase 3 전환을 보고함.

영향 약물: survodutide · id: NCT09000104 · detail: survodutide phase 변경: Phase 2 -> Phase 3

efficacy survodutide의 Boehringer이 2026-04-26에 primary completion 일정을 2026-11 -> 2027-11로 변경함.

영향 약물: survodutide · id: NCT09000104 · detail: survodutide primary completion 변경: 2026-11 -> 2027-11

efficacy pemvidutide의 Altimmune이 2026-04-26에 status Active, not recruiting -> Completed 변경을 보고함.

영향 약물: pemvidutide · id: NCT09000105 · detail: pemvidutide status 변경: Active, not recruiting -> Completed

efficacy pemvidutide의 Altimmune이 2026-04-26에 결과(results posted)를 등록함.

영향 약물: pemvidutide · id: NCT09000105 · detail: pemvidutide results posted (이전 False -> 현재 True)

safety pemvidutide의 Altimmune trial에서 2026-04-26에 신규 AE term(transient lipase elevation)이 보고됨.

영향 약물: pemvidutide · id: NCT09000105 · detail: 새 AE term 추가: transient lipase elevation

efficacy aldafermin의 NGM Bio이 2026-04-26에 결과(results posted)를 등록함.

영향 약물: aldafermin · id: NCT09000108 · detail: aldafermin results posted (이전 False -> 현재 True)

pipeline efruxifermin의 Akero이 2026-04-26에 phase Phase 2b -> Phase 3 전환을 보고함.

영향 약물: efruxifermin · id: NCT09000102 · detail: efruxifermin phase 변경: Phase 2b -> Phase 3

pipeline efruxifermin의 Akero이 2026-04-26에 status Active, not recruiting -> Recruiting 변경을 보고함.

영향 약물: efruxifermin · id: NCT09000102 · detail: efruxifermin status 변경: Active, not recruiting -> Recruiting

efficacy efruxifermin의 Akero이 2026-04-26에 primary completion 일정을 2026-09 -> 2027-09로 변경함.

영향 약물: efruxifermin · id: NCT09000102 · detail: efruxifermin primary completion 변경: 2026-09 -> 2027-09

safety efruxifermin의 Akero trial에서 2026-04-26에 신규 AE term(transient ALT elevation)이 보고됨.

영향 약물: efruxifermin · id: NCT09000102 · detail: 새 AE term 추가: transient ALT elevation

efficacyregulatory semaglutide-2.4의 Novo Nordisk이 2026-04-26에 status Active, not recruiting -> Completed 변경을 보고함.

영향 약물: semaglutide-2.4 · id: NCT09000111 · detail: semaglutide-2.4 status 변경: Active, not recruiting -> Completed

efficacyregulatory semaglutide-2.4의 Novo Nordisk이 2026-04-26에 결과(results posted)를 등록함.

영향 약물: semaglutide-2.4 · id: NCT09000111 · detail: semaglutide-2.4 results posted (이전 False -> 현재 True)

FDA news diff (synthetic)

regulatory resmetirom에 대해 2026-04-26에 FDA regulatory 항목이 게시됨: Synthetic accelerated approval converted to traditional approval for THR-beta agent (synthetic).

영향 약물: resmetirom · id: FDA-SYN-2026-0414 · detail: 신규 FDA 항목: Synthetic accelerated approval converted to traditional approval for THR-beta agent (synthetic)

safetyregulatory denifanstat에 대해 2026-04-26에 FDA safety 항목이 게시됨: Safety signal review opened for an investigational FASN inhibitor (synthetic).

영향 약물: denifanstat · id: FDA-SYN-2026-0415 · detail: 신규 FDA 항목: Safety signal review opened for an investigational FASN inhibitor (synthetic)

EMA EPAR (synthetic)

regulatory resmetirom에 대해 2026-04-26에 EMA regulatory 항목이 게시됨: CHMP positive opinion for synthetic THR-beta agonist in MASH (synthetic).

영향 약물: resmetirom · id: EMA-SYN-2026-0078 · detail: EMA: CHMP positive opinion for synthetic THR-beta agonist in MASH (synthetic)

safetyregulatory semaglutide-2.4, liraglutide, tirzepatide에 대해 2026-04-25에 EMA safety 항목이 게시됨: PRAC review of GLP-1 class hepatic safety signals (synthetic).

영향 약물: semaglutide-2.4, liraglutide, tirzepatide · id: EMA-SYN-2026-0079 · detail: EMA: PRAC review of GLP-1 class hepatic safety signals (synthetic)

PMDA news (synthetic)

regulatory survodutide에 대해 2026-04-26에 PMDA regulatory 항목이 게시됨: PMDA grants Sakigake-equivalent designation for synthetic GCG/GLP-1 dual agonist (synthetic).

영향 약물: survodutide · id: PMDA-SYN-2026-0033 · detail: PMDA: PMDA grants Sakigake-equivalent designation for synthetic GCG/GLP-1 dual agonist (synthetic)

Sponsor IR / SEC 8-K (synthetic)

efficacypipeline Madrigal이 2026-04-26에 IR/8-K 공시: Synthetic Q1 update: real-world synthetic MASH cohort interim data (synthetic) (resmetirom).

영향 약물: resmetirom · id: IR-MDGL-SYN-2026-04-26-01 · detail: Madrigal 8-K: Synthetic Q1 update: real-world synthetic MASH cohort interim data (synthetic)

efficacy Akero이 2026-04-26에 IR/PR 공시: Akero announces synthetic 96-week histology readout planning (synthetic) (efruxifermin).

영향 약물: efruxifermin · id: IR-AKRO-SYN-2026-04-26-02 · detail: Akero PR: Akero announces synthetic 96-week histology readout planning (synthetic)

pipeline 89bio이 2026-04-26에 IR/8-K 공시: 89bio synthetic ENLIGHTEN-Synth enrollment milestone (synthetic) (pegozafermin).

영향 약물: pegozafermin · id: IR-ETNB-SYN-2026-04-26-03 · detail: 89bio 8-K: 89bio synthetic ENLIGHTEN-Synth enrollment milestone (synthetic)

safetyefficacy Altimmune이 2026-04-26에 IR/PR 공시: Altimmune synthetic IMPACT-Synth topline summary released (synthetic) (pemvidutide).

영향 약물: pemvidutide · id: IR-ALT-SYN-2026-04-26-04 · detail: Altimmune PR: Altimmune synthetic IMPACT-Synth topline summary released (synthetic)

safety Inventiva이 2026-04-26에 IR/PR 공시: Inventiva synthetic NATIV3-Synth DSMB safety review reaffirms continuation (synthetic) (lanifibranor).

영향 약물: lanifibranor · id: IR-IVA-SYN-2026-04-26-05 · detail: Inventiva PR: Inventiva synthetic NATIV3-Synth DSMB safety review reaffirms continuation (synthetic)

AASLD The Liver Meeting 2026 abstracts (synthetic)

efficacy AASLD 2026(synthetic) abstract: resmetirom - Long-term resmetirom exposure and synthetic real-world fibrosis regression (synthetic).

영향 약물: resmetirom · id: AASLD-SYN-2026-001 · detail: AASLD abstract (efficacy): Long-term resmetirom exposure and synthetic real-world fibrosis regression (synthetic)

efficacy AASLD 2026(synthetic) abstract: efruxifermin - Efruxifermin synthetic 96-week histology readout (synthetic).

영향 약물: efruxifermin · id: AASLD-SYN-2026-002 · detail: AASLD abstract (efficacy): Efruxifermin synthetic 96-week histology readout (synthetic)

efficacy AASLD 2026(synthetic) abstract: pemvidutide - Pemvidutide synthetic IMPACT-Synth topline (synthetic).

영향 약물: pemvidutide · id: AASLD-SYN-2026-003 · detail: AASLD abstract (efficacy): Pemvidutide synthetic IMPACT-Synth topline (synthetic)

efficacy AASLD 2026(synthetic) abstract: survodutide - Survodutide MASH synthetic dose-response (synthetic).

영향 약물: survodutide · id: AASLD-SYN-2026-004 · detail: AASLD abstract (efficacy): Survodutide MASH synthetic dose-response (synthetic)

safetyefficacy AASLD 2026(synthetic) abstract: pegozafermin - Pegozafermin F4 synthetic interim safety (synthetic).

영향 약물: pegozafermin · id: AASLD-SYN-2026-005 · detail: AASLD abstract (safety): Pegozafermin F4 synthetic interim safety (synthetic)

safety AASLD 2026(synthetic) abstract: lanifibranor - Lanifibranor synthetic NATIV3-Synth DSMB update (synthetic).

영향 약물: lanifibranor · id: AASLD-SYN-2026-006 · detail: AASLD abstract (safety): Lanifibranor synthetic NATIV3-Synth DSMB update (synthetic)

safety AASLD 2026(synthetic) abstract: denifanstat - Denifanstat synthetic alopecia adjudication (synthetic).

영향 약물: denifanstat · id: AASLD-SYN-2026-007 · detail: AASLD abstract (safety): Denifanstat synthetic alopecia adjudication (synthetic)